Indagare sulla chemioterapia della vescica invece della chirurgia per il cancro alla vescica a basso rischio (CALIBER)
CALIBER - Studio di fattibilità randomizzato di fase II sulla chemiosezione e gestione chirurgica nel carcinoma della vescica non muscolo-invasivo a basso rischio
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic. This multicentre study aims to establish the short term efficacy of chemoresection using chemotherapy within the bladder for the treatment of NMIBC.
Should the levels of complete response following chemoresection meet predefined criteria, a larger phase III trial would be developed to assess longer term disease related endpoints, with the aim of standardising management of recurrent low risk NMIBC and potentially removing the need for over a thousand patients each year to undergo surgery.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
CALIBER is a two stage phase II, multicentre, randomised controlled trial (RCT). A control group has been included to provide prospective data about surgical management and outcomes and assess feasibility of recruitment to a randomised study.
Stage 1: 80 patients will be recruited with treatment allocated 2:1 by randomisation between chemoresection and surgical management.
Stage 2: If the stop/go activity criteria at the end of stage 1 indicate that recruitment should continue, 9 additional participants will be recruited, all of whom will receive chemoresection.
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg Mitomycin C (MMC) as outpatients. This treatment will be delivered via catheter under local anaesthetic.
Patients assigned to the surgical management group will receive the standard surgical management in use at their hospital for treatment of recurrence which may include a single post-operative installation of 40mg MMC within 24 hours.
All participants will be followed up at 3 weeks from the start of treatment (ie at time of final MMC instillation for chemoresection group) and each will receive a cystoscopy three months from the end of treatment to assess response, in accordance with European Association of Urology (EAU) guidelines.
Subsequent cystoscopic follow up will take place 12 months after treatment if recurrence-free at 3 months and then annually.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
London, Regno Unito, NW1 2BU
- University College Hospital
-
Manchester, Regno Unito, M23 9LT
- Wythenshawe Hospital
-
Manchester, Regno Unito, M20 2LR
- Withington Hospital
-
-
Cheshire
-
Macclesfield, Cheshire, Regno Unito, SK10 3BL
- Macclesfield District General Hospital
-
-
Cleveland
-
Middlesbrough, Cleveland, Regno Unito, TS4 3BW
- James Cook University Hospital
-
-
Cumbria
-
Whitehaven, Cumbria, Regno Unito, CA28 8JG
- West Cumberland Hospital
-
-
Devon
-
Exeter, Devon, Regno Unito, EX2 5DW
- Royal Devon and Exeter Hospital
-
Plymouth, Devon, Regno Unito, PL6 8DH
- Derriford Hospital
-
-
Dorset
-
Bournemouth, Dorset, Regno Unito, BH7 7DW
- Royal Bournemouth Hospital
-
Dorchester, Dorset, Regno Unito, DT1 2JY
- Dorset County Hospital
-
-
England
-
Carlisle, England, Regno Unito, CA2 7HY
- Cumberland Infirmary
-
-
Essex
-
Chelmsford, Essex, Regno Unito, CM1 5ET
- Broomfield Hospital
-
Harlow, Essex, Regno Unito, CM20 1QX
- Princess Alexandra Hospital
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, Regno Unito, GL53 7AN
- Cheltenham General Hospital
-
Gloucester, Gloucestershire, Regno Unito, GL1 3NN
- Gloucestershire Royal Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, Regno Unito, OL1 2JH
- Royal Oldham Hospital
-
-
Hampshire
-
Basingstoke, Hampshire, Regno Unito, RG24 9NA
- Basingstoke and North Hampshire Hospital
-
Southampton, Hampshire, Regno Unito, SO16 6YD
- Southampton General Hospital
-
-
Herefordshire
-
Hereford, Herefordshire, Regno Unito, HR1 2ER
- Hereford County Hospital
-
-
Kent
-
Dartford, Kent, Regno Unito, DA2 8DA
- Darent Valley Hospital
-
Gillingham, Kent, Regno Unito, ME7 5NY
- Medway Maritime Hospital
-
-
Lancashire
-
Preston, Lancashire, Regno Unito, PR2 9HT
- Royal Preston Hospital
-
-
Leicestershire
-
Leicester, Leicestershire, Regno Unito, LE5 4PW
- Leicester General Hospital
-
-
Middlesex
-
Harrow, Middlesex, Regno Unito, HA1 3UJ
- Northwick Park Hospital
-
-
Oxfordshire
-
Headington, Oxfordshire, Regno Unito, OX3 7LE
- Churchill Hospital
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Regno Unito, S10 2JF
- Royal Hallamshire Hospital
-
-
Suffolk
-
Ipswich, Suffolk, Regno Unito, IP4 5PD
- Ipswich Hospital
-
-
Surrey
-
Croydon, Surrey, Regno Unito, CR7 7YE
- Croydon University Hospital
-
Guildford, Surrey, Regno Unito, GU2 7XX
- Royal Surrey County Hospital
-
-
Tyne and Wear
-
Newcastle upon Tyne, Tyne and Wear, Regno Unito, NE7 7DN
- Freeman Hospital
-
-
West Midlands
-
Wolverhampton, West Midlands, Regno Unito, WV10 0QP
- New Cross Hospital
-
-
West Sussex
-
Chichester, West Sussex, Regno Unito, PO19 6SE
- St Richard's Hospital
-
Worthing, West Sussex, Regno Unito, BN11 2DH
- Worthing Hospital
-
-
West Yorkshire
-
Wakefield, West Yorkshire, Regno Unito, WF1 4DG
- Pinderfields General Hospital
-
-
Worcestershire
-
Kidderminster, Worcestershire, Regno Unito, DY11 6RJ
- Kidderminster Hospital
-
Redditch, Worcestershire, Regno Unito, B98 7UB
- Alexandra Hospital
-
Worcester, Worcestershire, Regno Unito, WR5 1DD
- Worcester Royal Hospital
-
-
Yorkshire
-
Leeds, Yorkshire, Regno Unito, LS9 7TF
- St James's University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Written informed consent
- NMIBC recurrence following original diagnosis of low risk NMIBC (defined as Ta G1 or Ta G2 (Ta low grade) with a risk of recurrence score of ≤6 using EORTC risk tables
- Histologically confirmed Transitional-cell carcinoma (TCC) at original diagnosis
- Aged 16 or over
- Satisfactory pre-treatment haematology values and serum creatinine < 1.5 x Upper Limit of Normal (ULN)
- Negative pregnancy test for women of child-bearing potential
Exclusion Criteria:
- Any history of: grade 3/high grade or ≥T1 transitional cell carcinoma, concomitant carcinoma in situ, more than 7 tumours at one diagnosis or more than 1 recurrence per year since initial diagnosis or in the past five years, whichever is shorter
- Any history of histologically confirmed non-TCC bladder cancer
- Trial entry recurrence identified within 11.5 months of the date of the original diagnosis
- Any prior treatment of the trial entry recurrence (including biopsy)
- Previous MMC chemotherapy other than a single instillation at diagnostic surgery
- Known allergy to MMC
- Carcinoma involving the prostatic urethra or upper urinary tract (participants should have had imaging of the upper urinary tract within 2 years prior to randomisation)
- Known or suspected reduced bladder capacity (<100ml)
- Significant bleeding disorder
- Female patients who are breast-feeding or are of childbearing potential and unwilling or unable to use adequate non-hormonal contraception. Male patients should also use contraception if sexually active.
- Active or intractable urinary tract infection
- Urethral stricture or anything impeding the insertion of a catheter
- Large narrow neck diverticula
- Significant urinary incontinence
- Any other conditions that in the Principal Investigator's opinion would contraindicate protocol treatment
- Unable or unwilling to comply with study procedures or follow up schedule
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Chemoresection
4 once weekly outpatient intravesical instillations 40mg Mitomycin C |
Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
Altri nomi:
|
|
Altro: Surgical Management
Surgical management according to local practice |
Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Complete response rate with chemoresection
Lasso di tempo: 3 months
|
Defined as an absence of any tumour following chemoresection and will be assessed visually at 3 month check cystoscopy by patients' urologists. A biopsy of the tumour bed would take place to confirm visual assessment of complete response. |
3 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Treatment compliance in chemoresection group
Lasso di tempo: Duration of treatment (3 weeks)
|
Patients who receive 4 MMC instillations with no more than 14 days between each instillation will be described as fully compliant. |
Duration of treatment (3 weeks)
|
|
Salvage surgery rates
Lasso di tempo: 3 years
|
Assessing trans-urethral resection and biopsy rates following initial treatment in both treatment groups |
3 years
|
|
Progression-free survival
Lasso di tempo: 3 years
|
Defined as time from randomisation to the first of muscle invasive bladder recurrence, recurrence in the pelvic nodes, distant metastatic recurrence or death from any cause. |
3 years
|
|
Toxicity (NCI Common Toxicity Criteria for Adverse Effects (CTCAE) V4 and Clavien Dindo grade (in surgical group))
Lasso di tempo: up to 12 months
|
Measuring side effects of both treatments using clinician reported toxicity scales |
up to 12 months
|
|
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Superficial Bladder Cancer (BLS24) questionnaire
Lasso di tempo: up to 12 months
|
Assessing side effects and impact of both treatments on patient reported quality of life. |
up to 12 months
|
|
Health service utilisation
Lasso di tempo: up to 12 months
|
Assessed using prospective data collection of health resource usage. |
up to 12 months
|
|
Recurrence free interval
Lasso di tempo: up to 12 months
|
Time from end of treatment to first relapse, in patients confirmed recurrence free at 3 months |
up to 12 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Hugh Mostafid, Royal Surrey County Hospital NHS Foundation Trust
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie urologiche
- Malattie della vescica urinaria
- Neoplasie della vescica urinaria
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Indoli
- Quinones
- Azirines
- Mitomicina
- Indolequinoni
- Mitomicina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ICR-CTSU/2013/10041
- 2013-005095-18 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .